Plant produced anti-HIV and anti-HSV antibodies. Phase 1 clinical trial ends Q3 2018. The next generation of MB66 will include an anti-sperm human contraceptive antibody (HCA).
Clinical – Phase 1 Trial (C1)
Delivery Route & Method:
Topical - Film - Vaginal
Mechanism of Action:
virus neutralization, mucus trapping
- Mapp Biopharmaceutical, Inc.
- Nat. Institute Allergy & Infect. Diseases (NIAID)
- Monoclonal Antibodies